I’m looking for people who are comfortable with video production and are into biotechnology. If that’s you (or someone you know), please drop me a line.
The following reports are available through this special offer:
|Drug Patent Challenge Report
The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drug patents since 2000.
Currently selling for $800 in the DrugPatentWatch Report Store.
|Orphan Drug Report
The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity since 2000.
Currently selling for $500 in the DrugPatentWatch Report Store.
|Individual Country Drug Patent Inventor Reports
These Individual Country Drug Patent Inventor Reports profile the individuals who have been awarded pharmaceutical drug patents since 2000.
These reports currently sell for $195 to $795 in the DrugPatentWatch Report Store.
To take advantage of this offer:
Biotechnology company management presents several challenges relative to other industries. Firstly, many biotechnology managers come from scientific backgrounds and find their way into management positions with little formal management training. Secondly the tenure of managers may be short, and movement to new companies can bring new responsibilities, a different corporate culture, and a different external environment. Finally, the biotechnology industry is in a state of flux, with health care reform, pricing pressures, and the combined forces of globalization, offshoring, and increased outsourcing. So, it is with great interest that I read Practical Leadership for Biopharmaceutical Executives.
Author Jane Chin has a diverse background as founder and president of the Medical Science Liaison Institute, as managing partner in a management consulting firm, and with a certificate in competitive intelligence. In writing the book, Chin arranged it into seven chapters, each of which is presented in the style of a journal paper, complete with abstract and keywords. The book is primarily directed at middle and upper level management, and is also intended to serve a larger audience of organizational development consultant, C and E level executives, venture capitalists, and students. The chapters cover leadership as a phenomenon; management leadership competencies; presence, stewardship, and development; self-concept as a leader; and, a new model for pharmaceutical leadership.
While I applaud Chin’s definition of the role and responsibilities of leaders, I fear that the book does not serve the audience the jacket copy describes as its target. The introduction, for example, describes the methodology and conclusions of a study of biopharmaceutical executive leadership themes which is comprised of an analysis of 50,000 words transcribed from interview notes. It is excellent material, but seems better suited to a management journal than to a book. The remaining chapters follow a similar style, describing case studies and frameworks focused on biopharmaceutical management. The dense academic style of this book seems best suited to high-level specialized students and to career coaches and human resource professionals — those who manage managers.
Looking for biotechnology industry reference information? You could hop on the Internet and search among the myriad sites, figure out which ones are credible, then try and find a consensus, or you could grab a copy of Plunkett’s Biotech & Genetics Industry Almanac. This book is essentially a reference librarian in a box. I reviewed an earlier issue of this book several years ago (my endorsement is on the front cover), so I wondered how useful it might remain despite the advancement of search engines and new web resources. In short, I think the book is still very valuable.
Plunkett’s Almanac profiles the top companies and has statistics and trends in the areas of genomics, proteomics, biopharmaceuticals, research, business development, and commercialization. The book is split into several sections:
At > 500 pages, the book represents a significant resource. A great deal of effort has gone into selecting valuable information and assembling it into a useful, objective, format. I recommend this book for biotechnology service firms needing the indexes of companies and knowledge of major trends, as well as for individuals in finance, market research, or other broad industry roles.
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|VITRASERT||Bausch And Lomb||ganciclovir||5,378,475||Jan 3, 2012|
|LUNESTA||Sunovion Pharms Inc||eszopiclone||6,319,926||Jan 16, 2012|
|LUNESTA||Sunovion Pharms Inc||eszopiclone||7,381,724||Jan 16, 2012|
|PREFEST||Teva Womens||estradiol; norgestimate||5,382,573||Jan 17, 2012|
|VIDEX||Bristol Myers Squibb||didanosine||5,880,106*PED||Jan 22, 2012|
|OCTREOSCAN||Mallinckrodt||indium in-111 pentetreotide kit||5,384,113||Jan 24, 2012|
|TASMAR||Valeant Pharm Intl||tolcapone||5,236,952||Jan 29, 2012|
|PROTOPIC||Astellas||tacrolimus||5,385,907||Jan 31, 2012|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com